Rezolute Inc. Common Stock (NV) (RZLT)
Stock · NASDAQ · Health Care
$3.56as of 10/16/2026
Price chart
Active signals
RZLT Signal Track Record
How signals performed across all stocks →What RZLT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 44 | +7.1% | 59% | September 24, 2026 |
| Bollinger Band Breakout | 29 | +3.4% | 59% | October 8, 2026 |
| Bollinger Band Breakdown | 19 | +1.3% | 58% | September 9, 2026 |
| 200-Day Moving Average TouchActive now | 10 | -2.1% | 30% | September 9, 2026 |
| Any 20-session window (baseline) | +2.6% | 56% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About RZLT
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly kn…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 58
- Website
- www.rezolutebio.com/
Fundamentals
- 1-day range
- $3.56$3.99
- Market cap
- $452.57M
- P/E (trailing)
- —
- P/E (forward)
- -7.69
- EPS (trailing)
- $-0.75
- Dividend yield
- —
- Beta
- 0.57
- Avg. volume
- 1.49M
- Dividend pay date
- October 13, 2020
Forecasts
10 analyst ratings
Rezolute Inc. Common Stock (NV) Competitors
Chosen by industry and closest market cap.
- RZLTRezolute Inc. Common Stock (NV)$3.58▼ 8.21%Market cap $452.57MP/E —$1.07$11.46
- BNTCBenitec Biopharma Inc. Common Stock$8.11▼ 4.14%Market cap $451.07MP/E —$8.52$16.76
- PRTAProthena Corporation plc Ordinary Shares$8.35▼ 1.76%Market cap $449.19MP/E —$7.73$11.8
- LRMRLarimar Therapeutics Inc. Common Stock$1.99▼ 0.25%Market cap $436.31MP/E —$2.06$6.42
- EVMNEvommune Inc. Common Stock$5.17▼ 12.82%Market cap $481.93MP/E —$6.52$33.2
- QTTBQ32 Bio Inc. Common Stock$7.52▼ 3.22%Market cap $482.18MP/E 7.95$1.91$23.57
- ASMBAssembly Biosciences Inc. Common Stock$20.09▼ 2.33%Market cap $420.36MP/E 333.50$19.98$39.71
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| RZLT Rezolute Inc. Common Stock (NV) | $452.57M | — | $3.58 | ▼ 8.21% | $1.07$11.46 |
| BNTC Benitec Biopharma Inc. Common Stock | $451.07M | — | $8.11 | ▼ 4.14% | $8.52$16.76 |
| PRTA Prothena Corporation plc Ordinary Shares | $449.19M | — | $8.35 | ▼ 1.76% | $7.73$11.8 |
| LRMR Larimar Therapeutics Inc. Common Stock | $436.31M | — | $1.99 | ▼ 0.25% | $2.06$6.42 |
| EVMN Evommune Inc. Common Stock | $481.93M | — | $5.17 | ▼ 12.82% | $6.52$33.2 |
| QTTB Q32 Bio Inc. Common Stock | $482.18M | 7.95 | $7.52 | ▼ 3.22% | $1.91$23.57 |
| ASMB Assembly Biosciences Inc. Common Stock | $420.36M | 333.50 | $20.09 | ▼ 2.33% | $19.98$39.71 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Rezolute Completes Enrollment In Open-Label Phase 3 Study Of Ersodetug In Tumor HI; Topline Data Expected In Mid-December 2026benzinga · 10/14/2026
- This NetApp Analyst Turns Bullish; Here Are Top 5 Upgrades For WednesdayBenzinga · 10/7/2026
- Lake Street Maintains Buy on Rezolute, Raises Price Target to $12Benzinga · 10/6/2026
- Citizens Maintains Market Outperform on Rezolute, Raises Price Target to $15Benzinga · 10/6/2026
- This Boyd Gaming Analyst Turns Bullish; Here Are Top 5 Upgrades For TuesdayBenzinga · 10/6/2026
- Cantor Fitzgerald Upgrades Rezolute to OverweightBenzinga · 10/6/2026
- These stocks are moving in today's after hours sessionChartMill · 10/5/2026
- Rezolute Gets FDA Nod For Pre-BLA Meeting Despite Phase 3 Miss — Retail Expects ‘Huge Rerating’Yahoo · 10/5/2026
- Rezolute Says FDA Recommends Pre-BLA Meeting for Congenital Hyperinsulinism TreatmentYahoo · 10/5/2026
Insider Activity
Insider Actions →- Sunil Ratilal Karnawat · September 2, 2026 · Tax Withholding2.3K @ $4.5
- Brian Kenneth Roberts · July 2, 2026 · Tax Withholding3.1K @ $4.99
- Daron Evans · July 2, 2026 · Tax Withholding3.1K @ $4.99
- Nevan C. Elam · July 2, 2026 · Tax Withholding8.0K @ $4.99
Institutional Ownership
March 31, 2026
- Total shares held
- 83.96M
- Total value held
- $254.91M
- Institutional holders
- 122
- Unknown12.99M
- Unknown9.18M
- Unknown6.31M
- Unknown6.30M
- Unknown5.05M
- Unknown3.52M
- Unknown3.44M
- Unknown3.33M
- Unknown2.97M
- Unknown2.75M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Rezolute Q4 EPS Misses Estimates, Reports Fiscal 2026 Results
Rezolute reported fourth-quarter and full-year fiscal 2026 financial results, with an EPS of $(0.20) missing the expected $(0.15). The company also provided a business update alongside these figures. The stock is currently trading near its support level, reflecting the market's reaction to the earnings miss.
Rezolute Q4 EPS Misses Estimates, Reports Fiscal 2026 Results. Rezolute reported fourth-quarter and full-year fiscal 2026 financial results, with an EPS of $(0.20) missing the expected $(0.15). The company also provided a business update alongside these figures. The stock is currently trading near its support level, reflecting the market's reaction to the earnings miss.